Gilead Sciences’ Bixlenvo turns up to 11 HIV pills into one, but who benefits most?
Gilead Sciences has secured U.S. Food and Drug Administration approval for Bixlenvo, a once-daily tablet combining bictegravir and lenacapavir for virologically suppressed adults with HIV, including patients whose resistance or treatment history has kept them on complex multi-tablet regimens.
